Karyopharm Therapeutics General and Administrative Expenses 2011-2026 | KPTI

General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.

What these expenses include

Salaries of administrative staff (executives, HR, accountants, legal personnel)
Office rent and utilities
Office equipment and IT infrastructure
Professional services (auditors, lawyers, consultants)
Insurance
General administrative travel and representation expenses

What the metric indicates

Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure
Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit
Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry
Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines

Annual General and Administrative Expenses Karyopharm Therapeutics

2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
115 M	132 M	145 M	144 M	126 M	105 M	48.8 M	24.9 M	23.9 M	21.6 M	15.9 M	5.88 M	2.43 M	1.84 M

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
145 M	1.84 M	65.3 M

Quarterly General and Administrative Expenses Karyopharm Therapeutics

2025-Q3	2025-Q2	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
26.6 M	28.5 M	-	27.6 M	31.1 M	29.5 M	-	30.8 M	34.5 M	35.9 M	-	34.6 M	37.3 M	38.8 M	-	35.1 M	36.5 M	37.6 M	-	31 M	30.8 M	30.7 M	-	25.3 M	24.7 M	27.1 M	-	13 M	9.49 M	7.62 M	-	5.82 M	6.64 M	6.26 M	-	5.9 M	5.96 M	5.55 M	-	4.76 M	6.16 M	5.4 M	-	3.81 M	3.31 M	2.9 M	-	1.58 M	943 K	879 K	-	672 K	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
38.8 M	672 K	18.7 M

General and Administrative Expenses of other stocks in the Biotechnology industry

Issuer	General and Administrative Expenses	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	78.3 M	-	2.43 %	$ 254 M	Germany
Acorda Therapeutics ACOR	89.7 M	-	-24.86 %	$ 820 K	USA
Adverum Biotechnologies ADVM	63.1 M	-	-	$ 86.2 M	USA
Amgen AMGN	7.05 B	$ 350.12	2.98 %	$ 188 B	USA
AlloVir ALVR	11 M	-	4.14 %	$ 49.1 M	USA
Amneal Pharmaceuticals AMRX	527 M	$ 12.68	2.92 %	$ 3.97 B	USA
Applied Molecular Transport AMTI	37.4 M	-	-	$ 10.1 M	USA
Applied Therapeutics APLT	20.6 M	-	-	$ 8.42 M	USA
argenx SE ARGX	308 M	$ 781.8	2.14 %	$ 25 B	Niderland
I-Mab IMAB	900 M	-	-	$ 866 M	China
Alexion Pharmaceuticals, Inc. ALXN	1.4 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	16.2 M	-	2.54 %	$ 160 B	France
Arcutis Biotherapeutics ARQT	275 M	$ 24.48	5.18 %	$ 3.11 B	USA
Biophytis SA BPTS	7.15 M	-	-13.47 %	$ 169 M	France
AVROBIO AVRO	24 M	-	1083.1 %	$ 745 M	USA
Ayala Pharmaceuticals AYLA	1.53 M	-	-	$ 7.46 M	Israel
AstraZeneca PLC AZN	15.2 B	-	-	$ 96.9 B	Britain
Midatech Pharma plc MTP	4.95 M	-	-18.52 %	$ 27.3 M	Britain
EyeGate Pharmaceuticals, Inc. EYEG	4.66 M	-	-1.52 %	$ 24.7 M	USA
Autolus Therapeutics plc AUTL	132 M	$ 1.5	9.93 %	$ 399 M	Britain
BeiGene, Ltd. BGNE	2.08 B	-	0.49 %	$ 251 B	Cayman-islands
Alterity Therapeutics Limited ATHE	5.51 M	$ 3.9	3.72 %	$ 9.38 B	Australia
BioNTech SE BNTX	286 M	$ 91.86	2.5 %	$ 27.2 B	Germany
CymaBay Therapeutics CBAY	52 M	-	-	$ 3.45 B	USA
Advaxis ADXS	12.2 M	-	-9.65 %	$ 45.9 M	USA
Aytu BioScience AYTU	17.4 M	$ 2.68	4.28 %	$ 16.8 M	USA
Burford Capital Limited BUR	99.3 M	$ 4.53	-0.22 %	$ 742 M	Britain
Avid Bioservices CDMO	26 M	-	-	$ 789 M	USA
Cidara Therapeutics CDTX	20.6 M	-	-	$ 1.41 B	USA
Институт стволовых клеток человека ISKJ	25.8 M	-	-	-	Russia
Cabaletta Bio CABA	29.6 M	$ 3.05	-0.65 %	$ 306 M	USA
Can-Fite BioPharma Ltd. CANF	3.05 M	$ 3.1	2.31 %	$ 6.75 B	Israel
Checkpoint Therapeutics CKPT	20.1 M	-	-	$ 169 M	USA
Cerus Corporation CERS	80.9 M	$ 1.92	4.08 %	$ 366 M	USA
Aeterna Zentaris AEZS	5.92 M	-	5.93 %	$ 314 M	Canada
Checkmate Pharmaceuticals CMPI	15.7 M	-	-	$ 231 M	USA
AgeX Therapeutics AGE	11 M	-	-10.17 %	$ 12.2 K	USA
Concert Pharmaceuticals CNCE	22.5 M	-	-	$ 401 M	USA
Aeglea BioTherapeutics AGLE	47.9 M	-	-	$ 1.01 B	USA
Applied Genetic Technologies Corporation AGTC	17 M	-	-	$ 26.5 M	USA
CTI BioPharma Corp. CTIC	84.8 M	-	-	$ 1.2 B	USA
AIkido Pharma AIKI	23.8 M	-	1.93 %	$ 17.4 M	USA
Aptose Biosciences APTO	13.4 M	-	-45.71 %	$ 1.2 M	Canada
Cyclacel Pharmaceuticals CYCCP	7.72 M	-	-4.36 %	$ 27 M	USA
Cellectar Biosciences CLRB	11.5 M	$ 2.81	2.18 %	$ 7.33 M	USA
Deciphera Pharmaceuticals DCPH	136 M	-	-	$ 2.18 B	USA
Akero Therapeutics AKRO	37.9 M	-	-	$ 3.67 B	USA
Dynavax Technologies Corporation DVAX	170 M	-	-	$ 2.02 B	USA
CureVac N.V. CVAC	100 M	-	-	$ 867 M	Germany
Cyclerion Therapeutics CYCN	5.34 M	$ 3.43	-1.43 %	$ 8.64 M	USA